SHLP2 vs Survodutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Side-by-Side Comparison
| Aspect | SHLP2 | Survodutide |
|---|---|---|
| Mechanism | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. |
| Typical Dosage | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. |
| Side Effects | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. |
| Best For |
Key Differences
Unique to SHLP2:
Unique to Survodutide:
Detailed Analysis
Commonalities
SHLP2 and Survodutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose SHLP2 for Fat Loss, Anti-Aging & Longevity. Choose Survodutide for Weight Loss, Liver Health.
Ready to Learn More?
Looking for trusted sources?